This is a practical choice that keeps injection volumes small while fitting within standard vial capacity
B12 injections are often necessary for individuals presenting with many of the symptoms mentioned and risk factors such as high alcohol intake, pernicious anemia, hereditary conditions, AIDS, and many digestive diseases
Alternatives: Some patients opt for injections for more targeted delivery and potentially quicker results
CagriSema, developed by Novo Nordisk, is a fixed-dose combination of cagrilintide (a long-acting amylin analog) and semaglutide (a GLP-1 receptor agonist)
The compound is not scheduled under the Controlled Substances Act and is not explicitly banned but it also lacks FDA approval and has no place on the 503A Bulk Drug Substances List, which is the only pathway for licensed compounding pharmacies to legally dispense it
Internal healing or wounds in hard-to-reach areas require injectable